From GlobeNewswire: 2025-02-10 07:00:00

Roivant reported financial results for the third quarter of 2024, with plans to develop Brepocitinib for cutaneous sarcoidosis. Progress in IMVT-1402 and Batoclimab development, along with ongoing LNP litigation, were highlighted. Roivant has over $5.2 billion in cash and marketable securities, with upcoming milestones expected in various indications through 2026.

Immunovant initiated trials for IMVT-1402 in Graves’ disease and difficult-to-treat rheumatoid arthritis. Roivant subsidiary, Priovant, announced a Phase 2 study of Brepocitinib for cutaneous sarcoidosis. Genevant’s legal proceedings against Moderna continue, with significant milestones expected in the coming years.

Roivant’s financial summary for the third quarter of 2024 showed consolidated cash, cash equivalents, and marketable securities of approximately $5.2 billion. Research and development expenses increased, but Roivant remains focused on advancing its pipeline and achieving key milestones.

Investor conference calls are scheduled to discuss Roivant’s financial results and corporate updates. Roivant aims to accelerate the development and commercialization of medicines, with a pipeline including IMVT-1402, Batoclimab, Brepocitinib, and Mosliciguat. Forward-looking statements emphasize the company’s commitment to improving patient lives through innovative therapies.



Read more at GlobeNewswire:: Roivant Reports Financial Results for the Third Quarter